NCT00309946 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 51
- units
- Participants
- groups
- description
- Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
- id
- BG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 44
- upper Limit
- 81
- value
- 64
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- title
- Female
- measurements
- group Id
- BG000
- value
- 42
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 51
- units
- Participants
- groups
- description
- Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
- id
- BG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 44
- upper Limit
- 81
- value
- 64
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- title
- Female
- measurements
- group Id
- BG000
- value
- 42
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle